- Home
- BMEA vs SILC Comparison
BMEA vs SILC Comparison
Compare BMEA & SILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- SILC
- Stock Information
- Founded
- BMEA 2017
- SILC 1987
- Country
- BMEA United States
- SILC Israel
- Employees
- BMEA N/A
- SILC N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- SILC Computer Manufacturing
- Sector
- BMEA Health Care
- SILC Technology
- Exchange
- BMEA Nasdaq
- SILC Nasdaq
- Market Cap
- BMEA 103.5M
- SILC 86.2M
- IPO Year
- BMEA 2021
- SILC 1994
- Fundamental
- Price
- BMEA $1.83
- SILC $15.49
- Analyst Decision
- BMEA Strong Buy
- SILC Hold
- Analyst Count
- BMEA 10
- SILC 1
- Target Price
- BMEA $17.70
- SILC N/A
- AVG Volume (30 Days)
- BMEA 683.1K
- SILC 25.9K
- Earning Date
- BMEA 08-05-2025
- SILC 07-31-2025
- Dividend Yield
- BMEA N/A
- SILC N/A
- EPS Growth
- BMEA N/A
- SILC N/A
- EPS
- BMEA N/A
- SILC N/A
- Revenue
- BMEA N/A
- SILC $58,651,000.00
- Revenue This Year
- BMEA N/A
- SILC $6.26
- Revenue Next Year
- BMEA N/A
- SILC $19.14
- P/E Ratio
- BMEA N/A
- SILC N/A
- Revenue Growth
- BMEA N/A
- SILC N/A
- 52 Week Low
- BMEA $1.29
- SILC $12.29
- 52 Week High
- BMEA $13.07
- SILC $18.61
- Technical
- Relative Strength Index (RSI)
- BMEA 56.62
- SILC 46.57
- Support Level
- BMEA $1.51
- SILC $15.03
- Resistance Level
- BMEA $1.86
- SILC $16.49
- Average True Range (ATR)
- BMEA 0.10
- SILC 0.81
- MACD
- BMEA 0.03
- SILC -0.15
- Stochastic Oscillator
- BMEA 91.67
- SILC 18.25
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.